TITLE

Battle of the Super Statins

AUTHOR(S)
Branca, Malorye A.; Sannes, Lucy
PUB. DATE
September 2006
SOURCE
Pharma DD: Tracking Discovery & Development;Sep/Oct2006, Vol. 1 Issue 2, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the efforts of pharmaceutical companies to produce combination pills in order to control the biggest share of the cholesterol-lowering market. It mentions that Lipitor or atorvastatin from Pfizer has long been controlling the market with worldwide sales of more than $12 billion. The buildup of atherosclerotic plaque is being reversed by the Crestor from AstraZeneca.
ACCESSION #
23475278

 

Related Articles

  • Do You Take Vytorin?  // Prevention;Apr2008, Vol. 60 Issue 4, p36 

    The article reports on a study of the cholesterol drug Vytorin. Vytorin is a combination of two cholesterol drugs, Zetia and Zocor, and was found to be no more effective than Zocor alone in reducing plaque. The study only included patients with a genetic abnormality that causes high cholesterol,...

  • Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect? Olivieri, Fabiola; Mazzanti, Ilaria; Abbatecola, Angela M.; Recchioni, Rina; Marcheselli, Fiorella; Procopio, Antonio D.; Antonicelli, Roberto // Current Vascular Pharmacology;Mar2012, Vol. 10 Issue 2, p216 

    Statins are well established drugs for primary and secondary prevention of coronary artery disease (CAD). Despite the well-known ability of statins to lower cholesterol, it is now clear that clinical benefits are also substantially higher than expected and several clinical trials, like JUPITER...

  • A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol. Tsuyoshi Nozue; Shingo Yamamoto; Shinichi Tohyama; Kazuki Fukui; Shigeo Umezawa; Yuko Onishi; Tomoyuki Kunishima; Kiyoshi Hibi; Mitsuyasu Terashima; Ichiro Michishita // American Journal of Cardiovascular Disease;2013, Vol. 3 Issue 4, p255 

    An aggressive reduction in low-density lipoprotein cholesterol (LDL-C) with statins produces regression or stabilization of coronary artery plaques. However, after achieving very low levels of LDL-C, atheroma regression is not observed in all patients. The purpose of the present study was to...

  • Addressing Statin Adverse Effects in the Clinic: The 5 Ms. Katz, Daniel H.; Intwala, Sunny S.; Stone, Neil J. // Journal of Cardiovascular Pharmacology & Therapeutics;Nov2014, Vol. 19 Issue 6, p533 

    With the release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, emphasis has been placed on using evidence-based intensity of therapy to reduce...

  • High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. Stegman, Brian; Rishi Puri; Cho, Leslie; Mingyuan Shao; Ballantyne, Christie M.; Barter, Phillip J.; Chapman, M. John; Erbel, Raimund; Libby, Peter; Raichlen, Joel S.; Kiyoko Uno; Yu Kataoka; Nissen, Steven E.; Nicholls, Stephen J. // Diabetes Care;Nov2014, Vol. 37 Issue 11, p3114 

    OBJECTIVE Although statins can induce coronary atheroma regression, this benefit has yet to be demonstrated in diabetic individuals. We tested the hypothesis that highintensity statin therapy may promote coronary atheroma regression in patients with diabetes. RESEARCH DESIGN AND METHODS The...

  • THE $10 BILLION PILL. Simons, John // Fortune;1/20/2003, Vol. 147 Issue 1, p58 

    Discusses the cholesterol-lowering drug atorvastatin calcium, or Lipitor, invented by Bruce Roth, vice president of chemistry at Pfizer. Possibility that the drug will become the world's first $10-billion-a-year drug; Sales of Lipitor in 2002; Market share that Lipitor has in the class of...

  • THE $10 BILLION PILL. Simons, John // Fortune International (Europe);1/20/2003, Vol. 147 Issue 1, p54 

    Discusses the cholesterol-lowering drug atorvastatin calcium, or Lipitor, invented by Bruce Roth, vice president of chemistry at Pfizer. Possibility that the drug will become the world's first $10-billion-a-year drug; Sales of Lipitor in 2002; Market share that Lipitor has in the class of...

  • SATURN and AIM-HIGH: 'Back down to planet Earth'. Martin, Seth S.; Blumenthal, Roger S. // Endocrine Today;Dec2011, Vol. 9 Issue 12, p1 

    The article discusses the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) and the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) trial.

  • Statin Treatment and Progression of Atherosclerotic Plaque Burden. Grobbee, Diederick E.; Bots, Michiel L. // Drugs;2003, Vol. 63 Issue 9, p893 

    Atherosclerosis is a progressive systemic disorder that, in the initial stages, is often asymptomatic. The measurement of atherosclerotic burden using imaging techniques enables the clinical benefits of lipid-modifying therapies to be assessed in early atherosclerosis and facilitates more rapid...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics